First-in-class iberdomide has been given accelerated approval under the Zenbexus brand name, alongside Johnson & Johnson and ...

Skylark Bio has started dosing patients in a phase 1/2 trial of SKY-GJB2, a one-shot gene therapy designed to treat ...

England is one of a handful of countries globally to have already exceeded the WHO benchmark of treating 80% of all known ...

Indeed, GLP-1 therapies currently bring with them the inconvenience of subcutaneous injections, the difficulty of titration, ...

Just a few weeks after filing for bankruptcy protection, Sangamo Therapeutics has found buyers for some of its key assets, including a Fabry disease therapy and its genomic medicine platforms. PTC ...

Cell and gene therapies are changing the way pharmaceutical organisations think about sample storage. From autologous ...

Actio is the third acquisition for Jazz in the last few years, coming after it bought Chimerix for $935 million last year and ...

Autolomous is a UK-based company pioneering cloud-native and AI-enhanced digitisation of life sciences manufacturing and ...

AbbVie, Bristol Myers Squibb, and Novartis have filed separate lawsuits in Illinois, each seeking to overturn a recently ...

Ex-BioNTech chief strategy officer Ryan Richardson is chief executive of the new outfit, which launches with $25 million in ...

There’s a personalisation crisis in today’s marketing. Nearly 99% of marketers believe personalisation helps strengthen ...

The approval makes the UK the first country in Europe to approve Foundayo (orforglipron), which becomes only the second product in the oral GLP-1 class to be cleared for use by the MHRA after Novo ...